The Patient Protection and Affordable Care Act (ACA) of 2010 includes key provisions that could lead to new and improved treatments, cures and cost savings for patients.  All of these changes will impact the biotechnology industry and the future of patient access to needed medicines.  This panel will address significant questions concerning the future of biotechnology under ACA and provide insights on what these changes mean for the industry, such as the impact of ACA on patient access to prescription drugs, biologics, and vaccines as well as implications of State decisions on Exchanges, benchmark benefit plans, and Medicaid expansion.  The role of industry in ACA on healthcare innovation and value-based initiatives will also be discussed.

Session ID: 2089

myBIO Chatter

Speakers (5)

contact_6471 Jonathan Blum Director, Center for Medicare Centers for Medicare and Medicaid Services
contact_8363 Marc Boutin Executive Vice President & Chief Operating Officer National Health Council
contact_10129 Scott Carmer Head, US Specialty Care AstraZeneca
contact_10024 Kristine Peterson Chief Executive Officer Valeritas, Inc
contact_1777 James Stansel Partner Sidley Austin LLP

Moderators (1)

contact_5623 Steve Usdin Washington Editor, BioCentury BioCentury This Week